Samsung Bio, waiting to break into peptides, nets $262M manufacturing deal with unnamed EU pharma

As Samsung Biologics works to close a massive buyout to branch out into peptides, the Korean CDMO’s bread-and-butter contracting work continues to gin up big-ticket contracts from the drug industry.